Launching with a commitment to understanding women and their health needs, and to identify urgently needed solutions.
Organon celebrates its launch as the only global company of its size focused on women’s health. In Asia Pacific including Japan, Organon will be led by Kaja Natland, a highly experienced executive in the biopharmaceutical industry. Employing over 1000 people in the Asia Pacific region, the company will focus on delivering impactful medicines and solutions for a healthier every day for women, their families and communities.
“We are very excited to launch Organon around the world. We build upon our strong foundation of more than 60 established medicines and solutions across a range of areas including reproductive health, heart disease, breast cancer, allergies, and asthma. As a new company, we will begin by listening to women’s healthcare needs, big and small, enabling us to explore treatments options — because we know there is so much more we can do for women and their health,” said Kaja.
Together with Kaja, Andreas Jorgensen has been appointed Managing Director for the South, East and Southeast Asia markets. He said, “With more than 2 billion people in this region, we are committed to making a world of difference in women’s health every day. The diversity of our business provides an established portfolio so we can look to invest in and advance new medicines and solutions for women that are so urgently needed. We believe the journey to improve women’s health is critical to achieving a healthier world.”
As a strategic hub for Organon, it opened its regional headquarters in Singapore to accelerate business growth in Asia Pacific. This is an affirmation of the company’s commitment to the country’s strategy to expand and further strengthen the biopharmaceutical industry. Organon Singapore Commercial Director Aman Sood, shared “We are thrilled that Organon has chosen Singapore as its head office for the Asia Pacific and Japan region. As we launch our new company, we are inspired to push past the limits of today and bring healthcare solutions to women and patients across the region.”
At launch, Organon’s portfolio will consist of more than 60 medicines and products across an international footprint that serves people in more than 140 markets, with nearly 80 per cent of its global US$6.5 billion in revenue generated outside the U.S. Organon believes it is well positioned for organic low-to-mid-single digit growth from its 2021 base of business. Organon has three core pillars that will benefit from renewed management focus and commercial investment: women’s health, biosimilars and established brands.
Organon’s R&D philosophy is to build a business around patient needs to identify and advance healthcare options for women that enable them to live their best lives every day.
“For too long, for too many common conditions, such as heavy, painful, and irregular menstrual bleeding, incontinence and menopause and many others, women have been told to accept and normalize these conditions as a part of life,” said Daniel Ruzicka, Medical Lead for Organon Asia Pacific & Japan. “Organon’s mission is to change this. We believe this approach will be very successful — the ability to identify diseases earlier, the ability to modify the course of diseases or healthcare conditions and to ultimately, improve the quality of life for women at all stages.”
The company’s extensive global capabilities in clinical development and patient safety, regulatory and medical affairs make it well-positioned to identify promising drugs, diagnostics and devices with the greatest potential to impact women’s health. [APBN]